IDEAYA Biosciences Selects IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types Markets June 12, 2023 [ad_1] IDEAYA Biosciences (IDYA) Selects IDE397 Part 2 Monotherapy Enlargement Dose For World Enrollment Concentrating on Excessive Precedence MTAP-Deletion Stable…
